Maplewood's Adopt-A-Family program sponsors families in need during the holiday season

SOUTH EASTON, MA / ACCESSWIRE / December 13, 2019 / Maplewood Country Day Camp & Enrichment Center was proud to hold its 16th annual Adopt-A-Family Winter Community Service Project to provide gifts for a family in need during the holiday season. The 2019 Adopt-A-Family program concluded on December 6th.

Maplewood Day Camp & Enrichment Center in South Easton, Massachusetts, has been family-owned and operated year-round since 1965. Maplewood is a community that encourages friendship, leadership, responsibility, and teamwork.

Through the Adopt-A-Family program, a family in need supplies a wish list. People in the community will then collect the items on the wish list and donate them. These items may include common household items, toiletries, winter clothing, toys, and more.

"Maplewood has a strong commitment to give back to the communities that surround us," says Lee Pinstein, co-director of Maplewood Day Camp & Enrichment Center.

"Throughout our 56-year history, we have forged strong relationships with many charitable organizations."

In addition to the Adopt-A-Family program, for every 2020 camp enrolment received from January 1, 2020, through February 15, 2020, Maplewood will contribute $50 to the School on Wheels nonprofit organization and local food pantries.

Maplewood also works closely with the DJ Dream Fund, which is a local scholarship program; supports local sports teams in the community; and is involved with community enrichment programs that support the arts, theater, museums, and schools.

For more information, please visit https://www.maplewoodyearround.com/

About Maplewood Day Camp & Enrichment Center

Maplewood's after school programs help children build confidence, boost academic performance, and promote physical well being, all while providing a safe and structured environment. The program includes transportation from Easton Public Schools, 30 acres of indoor and outdoor activities, academic assistance, and tutoring and convenient hours for families – until 6:30 p.m.

Maplewood also offers weekly programing for children ages 6 and younger, including bouncing in Maplewood's moonwalk, playing in the gym, participating in gymnastics, and visiting the play structures at the Village.

Families from all over the area have consistently recommended Maplewood Country Day Camp & Enrichment Center for instilling confidence in their children, providing them with positive enrichment activities and an unmatched quality of care.

Contact:

Lee Pinstein
Email: info@maplewoodyearround.com

SOURCE: Maplewood Country Day Camp

ReleaseID: 570173

NEW YORK, NY / ACCESSWIRE / December 13, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?prid=4868&wire=1
Lead Plaintiff Deadline: February 10, 2020
Class Period: August 8, 2017 to September 30, 2019

Allegations against ADMS include that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Merit Medical Systems, Inc. (NASDAQ:MMSI)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/merit-medical-systems-inc-loss-submission-form?prid=4868&wire=1
Lead Plaintiff Deadline: February 3, 2020
Class Period: February 26, 2019 to October 30, 2019

Allegations against MMSI include that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.

Baozun Inc. (NASDAQ:BZUN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/baozun-inc-loss-submission-form?prid=4868&wire=1
Lead Plaintiff Deadline: February 10, 2020
Class Period: Baozun American Depository Receipts between March 6, 2019 and November 20, 2019

Allegations against BZUN include that: (a) Baozun was heavily reliant upon a single brand partner, Huawei, for the exponential service fee growth it had been reporting historically, which was in turn fueling its historical revenue growth; (b) compared to other brands Baozun had as brand partners, the Huawei work had historically included a lot of additional add-on service fees, increasing the revenue reported from Huawei vis-a-via its other brand partners; (c) Huawei, like other large brands, was actively preparing to bring its online merchandising in-house, meaning Baozun knew that it was losing a significant brand partner; and (d) as a result of the foregoing, the Company was not on track to achieve the financial results and performance Defendants claimed the Company was on track to achieve during the class period.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 570169

NEW YORK, NY / ACCESSWIRE / December 13, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Energy Transfer LP (NYSE:ET)

Investors Affected : February 25, 2017 – November 11, 2019

A class action has commenced on behalf of certain shareholders in Energy Transfer LP. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Energy Transfer's permits to conduct the Mariner East pipeline project in Pennsylvania were secured via bribery and/or other improper conduct; (ii) the foregoing misconduct increased the risk that the Partnership and/or certain of its employees would be subject to government and/or regulatory action, thereby depreciating the Partnership's unit value; and (iii) as a result, the Partnership's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/energy-transfer-lp-loss-submission-form/?id=4871&from=1

Grubhub Inc. (NYSE:GRUB)

Investors Affected : July 30, 2019 – October 28, 2019

A class action has commenced on behalf of certain shareholders in Grubhub Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) customer orders were actually declining, despite the massive investments that the Company had made to spur demand for and use of its platform; (ii) Grubhub's new customer additions were generating significantly lower revenues as compared to historic cohorts because these customers were more prone to using competitor platforms; (iii) Grubhub's vaunted business model under which it secured exclusive partnerships had failed, and Grubhub needed to engage in the same aggressive nonpartnered sales tactics embraced by its competitors to generate significant revenue growth; (iv) Grubhub was required to spend substantial additional capital in order to grow revenues and retain market share in the face of heightened competitive dynamics and market saturation, eviscerating the Company's profitability; and (v) Grubhub was tracking tens of millions of dollars below its revenue and earnings guidance and such guidance lacked any reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/grubhub-inc-loss-submission-form/?id=4871&from=1

Prudential Financial, Inc. (NYSE:PRU)

Investors Affected : February 15, 2019 – August 2, 2019

A class action has commenced on behalf of certain shareholders in Prudential Financial, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company's reserve assumptions failed to account for adversely developing mortality experience in the Individual Life business segment; (b) the Company was not over-reserved, but instead, its reported reserves, particularly for the Individual Life business segment, were insufficient to satisfy its future policy benefits liabilities; and (c) the Company had materially understated its liabilities and overstated net income as a result of flawed assumptions in calculating mortality experience.

Shareholders may find more information at https://securitiesclasslaw.com/securities/prudential-financial-inc-loss-submission-form/?id=4871&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 570172

NEW YORK, NY / ACCESSWIRE / December 13, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

The RealReal, Inc. (NASDAQ:REAL)
Class Period: all persons and entities who purchased RealReal common stock pursuant and/or traceable to the Company's registration statement issued in connection with the Company's June 27, 2019 initial public offering.
Lead Plaintiff Deadline: January 24, 2020

During the class period, The RealReal, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's employees received little training on how to spot fake items; (2) the Company's strict quotas on its employees exacerbated product authentication issues; (3) consequently, the potential for counterfeit or mislabeled items to make it through Company's authentication process was higher than disclosed; and (4) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in REAL: http://www.kleinstocklaw.com/pslra-1/the-realreal-inc-loss-submission-form?id=4870&from=1

Infosys Limited (NYSE:INFY)
Class Period: July 7, 2018 to October 20, 2019
Lead Plaintiff Deadline: December 23, 2019

The complaint alleges Infosys Limited made materially false and/or misleading statements and/or failed to disclose that: (1) the Company improperly recognized revenues to inflate short-term profits; (2) Chief Executive Officer Salil Parekh bypassed reviews and approvals for large deals to avoid accounting scrutiny; (3) management pressured the Company's finance team to hide information from auditors and the Company's Board of Directors; and (4) as a result of the aforementioned misconduct, Defendants' statements about Infosys's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in INFY: http://www.kleinstocklaw.com/pslra-1/infosys-limited-loss-submission-form?id=4870&from=1

Under Armour, Inc. (NYSE:UA)
Class Period: August 3, 2016 to November 1, 2019
Lead Plaintiff Deadline: January 6, 2020

Under Armour, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) undisclosed to the investing public, the Company had been under investigation by and cooperating with the U.S. Department of Justice and U.S. Securities and Exchange Commission since at least July 2017; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in UA: http://www.kleinstocklaw.com/pslra-1/under-armour-inc-loss-submission-form?id=4870&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 570171

NEW YORK, NY / ACCESSWIRE / December 13, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Sealed Air Corporation (NYSE:SEE)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sealed-air-corporation-loss-submission-form?prid=4869&wire=1
Lead Plaintiff Deadline: December 31, 2019
Class Period: November 5, 2014 to August 6, 2018

Allegations against SEE include that: (a) Sealed Air had hired its auditor, E&Y, pursuant to a conflicted and improper process and in order to help facilitate defendants' efforts to engage in accounting fraud; (b) Sealed Air's deduction of $1.49 billion in connection with the Settlement was indefensible and done for the improper purpose of artificially inflating the Company's financial results; (c) Sealed Air had artificially inflated its earnings, cash flows, and operating income during the Class Period; (d) as a result of the above, Sealed Air's Class Period financial statements were materially false and misleading and not prepared in conformance with GAAP; and (e) as a result of the above, Sealed Air's statements regarding its financial results, business, and prospects were materially misleading.

Pareteum Corporation (NASDAQ:TEUM)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/pareteum-corporation-loss-submission-form?prid=4869&wire=1
Lead Plaintiff Deadline: December 23, 2019
Class Period: December 14, 2017 to October 21, 2019

Allegations against TEUM include that: (a) it was not true that the Company's purported success was the result of hyper-demand for Pareteum's unique products or exceptional service, or the Company's competent management; but, in fact, Defendants had propped up the Company's results by manipulating Pareteum's accounting for revenues, income, and the important Backlog metric; (b) Defendants had materially overstated the Company's profitability by failing to properly account for the Company's results of operations and by artificially inflating the Company's financial results; (c) it was not true that Pareteum contained even the most minimally adequate systems of internal operational or financial controls necessary to assure that Pareteum's reported financial statements were true, accurate, and/or reliable; (d) as a result, it also was not true that the Company's financial statements and reports were prepared in accordance with GAAP and SEC rules; and (e) as a result of the aforementioned adverse conditions, Defendants lacked any reasonable basis to claim that Pareteum was operating according to plan, or that Pareteum could achieve the guidance sponsored and/or endorsed by Defendants.

Armstrong Flooring, Inc. (NYSE:AFI)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/armstrong-flooring-inc-loss-submission-form?prid=4869&wire=1
Lead Plaintiff Deadline: January 14, 2020
Class Period: March 6, 2018 to November 4, 2019

Allegations against AFI include that: (1) the Company had engaged in channel stuffing to artificially boost sales; (2) the Company's internal control over inventory levels was not effective; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 570170

VANCOUVER, BC / ACCESSWIRE / December 13, 2019 / Northern Dynasty Minerals Ltd. (TSX:NDM; NYSE American:NAK) ("Northern Dynasty" or the "Company") announces that the Company has priced its previously announced overnight marketed public offering of common shares of the Company (the "Common Shares"). The Company has entered into an underwriting agreement with a syndicate of underwriters led by Cantor Fitzgerald Canada Corporation, as lead underwriter and sole book-runner, and including BMO Nesbitt Burns Inc., H.C. Wainwright & Co., LLC. and TD Securities Inc. (collectively, the "Underwriters") for the sale of 36,500,000 Common Shares at a price of US$0.37 per Common Share (the "Issue Price") for gross proceeds of US$13,505,000 (the "Offering"). The Offering is expected to close on or about December 18, 2019.

Northern Dynasty has granted the Underwriters an over-allotment option (the "Over-Allotment Option") exercisable, in whole or in part, in the sole discretion of the Underwriters, to purchase up to an additional 5,475,000 Common Shares at the Issue Price for up to 30 days after the closing for potential gross proceeds to the Company of up to approximately US$2,025,750.

The Company will pay the Underwriters a cash commission equal to 7.5% of the gross proceeds of the Offering, including proceeds received from the exercise of the Over-Allotment Option.

The Offering will be made by way of a prospectus supplement (the "Prospectus Supplement") to the Company's existing Canadian base shelf prospectus (the "Base Shelf Prospectus") and related U.S. registration statement on Form F-10 (SEC File No. 333-229262) (the "Registration Statement"). The U.S. form of Base Shelf Prospectus is included in the Registration Statement. An updated final Prospectus Supplement including pricing information will be filed with the securities commissions in each of the provinces of Canada (other than Québec) and the United States Securities and Exchange Commission (the "SEC"). The Canadian Prospectus Supplement (together with the related Canadian Base Shelf Prospectus) will be available on SEDAR at www.sedar.com. The United States Prospectus Supplement (together with U.S. Base Shelf Prospectus and the Registration Statement) will be available on the SEC's website at www.sec.gov. Alternatively, the Prospectus Supplement may be obtained, when available, upon request by contacting the Company or Cantor Fitzgerald Canada Corporation in Canada, attention: Equity Capital Markets, 181 University Avenue, Suite 1500, Toronto, ON, M5H 3M7, email: ecmcanada@cantor.com; Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 499 Park Avenue, 6th Floor, New York, New York, 10022 or by email at prospectus@cantor.com.

In addition to the Offering, Northern Dynasty is proceeding with its previously announced non-brokered private placement of Common Shares (the "Concurrent Private Placement"). The Concurrent Private Placement will consist of 13,513,514 Common Shares at the Issuer Price for gross proceeds of US$5,000,000. No commission or finder's fee is payable to the Underwriters in connection with the Concurrent Private Placement. Common Shares issued pursuant to the Concurrent Private Placement will be subject to applicable resale restrictions, including a four month hold period under Canadian securities legislation.

Closing of the Offering and the Concurrent Private Placement are subject to the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange and the NYSE American. Closing of Offering is not conditional upon the closing of the Concurrent Private Placement and closing of the Concurrent Private Placement is not conditional on the closing of the Offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The securities being offered have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon by the accuracy or adequacy of the Prospectus Supplement, the Base Shelf Prospectus or the Registration Statement.

About Northern Dynasty Minerals Ltd.

Northern Dynasty is a mineral exploration and development company based in Vancouver, Canada. Northern Dynasty's principal asset, owned through its wholly owned, Alaska-based U.S. subsidiary, the Pebble Partnership, is a 100% interest in a contiguous block of 2,402 mineral claims in southwest Alaska, including the Pebble deposit. The Pebble Partnership is the proponent of the Pebble Project, an initiative to develop one of the world's most important mineral resources.

Ronald W. Thiessen
President & CEO

US Media Contact:
Dan Gagnier
Gagnier Communications
(646) 569-5897

Forward Looking Information and other Cautionary Factors

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively referred to as "forward-looking information"). The use of any of the words "expect", "plan", "update" and similar expressions are intended to identify forward-looking information or statements. These statements include expectations about the likelihood of completion of the Offering or the Concurrent Private Placement, the amount of funds to be raised, and the use of proceeds of the Offering and the Concurrent Private Placement, the anticipated closing of the Offering and the Concurrent Private Placement, the finalization of the Environmental Impact Study by the U.S. Army Corps of Engineers, the ability of the Company to proceed with permit applications for the development of the Pebble Project, the ability of the Company to obtain the necessary federal and state permits for the development of the Pebble Project and the ability of the Company to secure the required Canadian and US regulatory and stock exchange acceptances for the Offering. Although the Company believes the expectations expressed in its forward-looking statements are based on reasonable assumptions, such statements are subject to future events and third party discretion such as regulatory personnel. For more information on the Company, and the risks and uncertainties connected with its business, Investors should review the Company's home jurisdiction filings at www.sedar.com and its filings with the United States Securities and Exchange Commission at www.sec.gov.

SOURCE: Northern Dynasty Minerals Ltd.

ReleaseID: 570156

Cripps, who is the Founder of Flip Your Life and Build Your Empire, Recently Arranged for Two Kids from the Barrie Area to Get Room Makeovers

LOS ANGELES, CA / ACCESSWIRE / December 13, 2019 / Kristin Cripps, a highly successful Barrie real estate broker, is pleased to announce that she recently chose two local kids to get amazing room makeovers.

To read the heart-warming story about Cripps and the room makeovers, please check out https://www.simcoe.com/news-story/9453245-kids-get-dream-room-makeovers-from-barrie-real-estate-broker/?fbclid=iwar0iqxwadwoufuhmjf1srdvt54sg0ny_aipexgmj_yxkv2whdq_mtuky5km.

As the article noted, after launching the Kids Room Makeover Contest earlier in the year, Cripps was delighted to see countless entries come in. After careful consideration, she gave Loretta Psaila and Brett Noble brand-new rooms.

Cripps said she was impressed with the way Loretta gives half of any money she receives to a charity; in the past, Loretta has donated to local animal shelters and the Salvation Army. She was also touched by Brett's nomination and said she is pleased with the way his green BMX-themed room turned out (and bonus half-pipe she had constructed outside).

In addition to the recent room makeovers, Cripps is busy planning her next events through Flip Your Life and online courses with Build Your Empire.

Through her work with Flip Your Life and Build Your Empire, Cripps strives to teach people who are living paycheck to paycheck how real estate investing can help them to boost their income and start living their dream life sooner.

As Cripps noted, being short on cash is something that she is all-too familiar with. Cripps, who once worked as a bartender, and was no stranger to having three jobs, recalls plenty of days where money was extremely tight.

"About ninety-nine percent of my clients have one home. When they retire, they often have little to no savings besides what is in their home," Cripps said.

"They often buy another smaller home, and usually have about $100,000 left over. They usually have 3 kids and give each child $20,000, which leaves them with $40,000 to go on a trip or buy a car or boat," she said, adding that this approach bothers her, because she wants people to enjoy a great and prosperous life their entire life-not just possibly at retirement.

"The funds that can be made from real estate investments can be used to do whatever one wants and that's where people can change their circumstances, their experiences and how they give back to those around them."

About Kristin Cripps:

Kristin Cripps is the founder of Flip Your Life and Build Your Empire. Cripps helps teach people to live the life of their dreams by using the power of real estate investment-not just at retirement, but throughout the years. For more information, please visit https://www.simcoe.com/news-story/9453245-kids-get-dream-room-makeovers-from-barrie-real-estate-broker/?fbclid=iwar0iqxwadwoufuhmjf1srdvt54sg0ny_aipexgmj_yxkv2whdq_mtuky5km.
Kristin is also founder of an empowerment platform called I Can. I Will. WatchMe!

Kristincripps.com
Flipyourlife.com
Crippsrealty.com
IcanIWillWatchMe.com

Contact:
Kristin Cripps
kristin@buildyourempire.com
705-726-7000

SOURCE: Kristin Cripps

ReleaseID: 570165

The New Influencer CRM Tool Allows People to Easily Streamline their Influencer Communications in One User-Friendly Place

NEW YORK, NY / ACCESSWIRE / December 13, 2019 / The founders of HYPR are pleased to announce the launch of their new Influencer customer relationship management (CRM) tool.

To learn more about HYPR and their effective influencer marketing platform, please check out https://www.hyprbrands.com/influencer-marketing-platform.

As a company spokesperson noted, HYPR's new Influencer CRM tool allows users to streamline their influencer communications in one convenient place.

"Powered by the ubiquitous Salesforce CRM, our platform lets you send and store outreach communications through integrated email," the spokesperson noted, adding that with the new and user-friendly tool, users can keep important notes, files, and replies handy for their entire team.

The new Influencer CRM tool also allows people to record communications that are sent to other places such as emails, texts and Instagram messages; it will also automatically track any responses and alert the user with an email when an influencer responds.

As it turns out, the launch of the new Influencer CRM tool is not the only exciting news to come out of HYPR in recent weeks. The company also released its new Activation Dashboard, which helps to manage activations from outreach to agreement.

While activating influencers is a process that involves a number of steps, it does not have to be a stressful or overwhelming experience. Thanks to the new Activation Dashboard, users can quickly and easily track statuses and responses.

"Since the tool integrates with HYPR's Influencer Marketing Cloud, you'll be able to log outreach using our Influencer CRM, and also start measuring a campaign right away when it's signed," the spokesperson noted.

The Activation Dashboard includes a number of impressive features, including the ability to move individual activations between stages including candidate, negotiating, agreed and signed. Users can also see at a glance the posts, stories, influencers and total budget in each stage.

Both the new Influencer CRM tool and the Activation Dashboard help round out the platform as the all-in-one solution for brands looking to manage their influencer programs at scale.

About HYPR:

HYPR developed their platform to help marketers like themselves identify the ROI of influencer marketing. Since then, they have partnered with hundreds of Fortune 500 brands and top PR and marketing agencies to deliver tightly targeted campaigns to industries such as travel, beauty, entertainment, fashion and more. For more information, please visit https://www.hyprbrands.com/.

HYPR
250 Greenwich St.
New York, NY 10006

Contact:

Kayli Kunkel
info@hyprbrands.com
212-266-0067

SOURCE: HYPR

ReleaseID: 570164

Reports regulatory progress in Europe and imminent commencement of clinical trial

CHARLOTTESVILLE, VA / ACCESSWIRE / December 13, 2019 / Adial Pharmaceuticals, Inc. ("Adial") (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has completed validation of its genetic biomarker test for its planned Phase 3 trial. The Phase 3 trial is designed to study AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder.

Eurofins Genomics ("Eurofins"), a division of Eurofins Biopharma Services, a global scientific leader in bioanalytical testing, performed the laboratory validation of Adial's companion diagnostic genetic test using double strand Sanger sequencing and Fragment length analysis of polymerase chain reaction (PCR) products. These assays will be used for the analysis of patients' blood samples for genetic variants in defined genes caused by Single Nucleotide Polymorphisms or Fragment Length Polymorphisms. The acceptability of the assay validation will be evaluated further by the local ethics committees and regulatory authorities during the clinical trial application (CTA) assessments.

William Stilley, Chief Executive Officer of Adial Pharmaceuticals, commented, "Completion of the genetic test validation is a key milestone as we finalize preparations for our planned Phase 3 trial. By genetically pre-screening subjects prior to enrollment, our companion diagnostic genetic test allows us to only enroll those patients that have the genetic biomarkers indicating that they are expected to respond to AD04. We believe this approach will enhance the efficacy rates of AD04 in the trial and reduce the time and costs associated with conducting the trial. At the same time, we are making progress towards finalizing the necessary regulatory approvals in Europe and look forward to providing near-term updates on commencement of our Phase 3 clinical trial."

Elena Logan, Senior VP, Eurofins Biopharma Services, noted, "The genetic test met or exceeded all the necessary criteria for use in the upcoming Phase 3 trial. Adial is at the forefront of precision medicine, developing a personalized approach using a genetic companion diagnostic test to identify patients likely to respond to treatment. We are delighted to support Adial in this important mission to advance AD04 as an attractive potential therapy addressing a significant unmet need among patients with Alcohol Use Disorder."

About Eurofins Scientific

Eurofins Scientific through its subsidiaries (hereinafter sometimes "Eurofins" or "the Group") believes it is a scientific leader in food, environment, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. With about 45,000 staff in more than 800 laboratories across 47 countries, Eurofins offers a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostics. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

About Eurofins BioPharma Services

Reliable, high quality laboratory data is pivotal to the success of clinical trials. Since laboratory testing is our sole focus, we go above and beyond to provide an array of services to ensure that any clinical trial sample is collected, transported, managed, analyzed, reported and stored to meet the objectives and purpose of your study. We are dedicated to providing the most cost effective and efficient solutions to pharmaceutical, biotech companies and CROs alike.

Eurofins BioPharma Services supports our customers with Central Laboratory (U.S., Netherlands, Singapore, China), Large and Small Bioanalytical (U.S., U.K., France), Phase 1/Early Development (France) and Immunology/Virology (U.S.) specialization laboratories globally. This provides our client base with true end-to-end laboratory solutions for your entire clinical phase development activity.

https://eurofinscentrallaboratory.com/biopharma-services

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. www.adialpharma.com

Forward Looking Statements

This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, genetically pre-screening subjects prior to enrollment allowing us to enhance the efficacy rates of AD04 in the trial and reducing the time and costs associated with conducting the trial, and the potential of AD04 to treat AUD other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to commence the Phase 3 clinical trials and enroll subjects as expected, our ability to enhance the efficacy rates of AD04 in the trial and reduce the time and costs associated with conducting the trial, our ability to expand the use of AD04 for use in patients with opioid use disorder, gambling and obesity, the ability of AD04 therapy to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2018, subsequent Quarterly Reports on Form 10-Q and Current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

Contact:

Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com

SOURCE: Adial Pharmaceutical, Inc.

ReleaseID: 570161